What is the Role of the Anti-Parasitic Drugs in the Treatment of Coronavirus Disease 2019? by Rahmati Roodsari, Sara & Arab-Mazar, Zahra
                                                                                                                           Novelty in Biomedicine 
NBM 31   Novelty in Biomedicine 2021, 1, 31-2 
Letter to Editor 
 
 
What is the Role of the Anti-Parasitic Drugs in the Treatment of 
Coronavirus Disease 2019? 
 
 
Sara Rahmati Roodsari1, Zahra Arab-Mazar 2,3* 
 
1 Functional  Neurosurgery  Research  Center,  Shohada  Tajrish  Comprehensive  Neurosurgical  Center  of  Excellence,  Shahid  
Beheshti University of Medical Sciences, Tehran, Iran 
2 Department of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran 
3  Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran 
 
 
Received: 18 August, 2020; Accepted: 07 December, 2020 
 
 
*Corresponding Author: Zahra Arab-Mazar, Department of Medical Parasitology and Mycology, School of Public Health, Tehran 
University of Medical Sciences, Tehran, Iran. Email: z.arabmazar@gmail.com, ORCID: 0000-0002-7823-9922  
 
Please cite this article as: Rahmati Roodsari S, Arab-Mazar Z. What is the role of the anti-parasitic drugs in the treatment of coronavirus 





Severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) is a rapidly emerging viral infection 
causing coronavirus disease 2019 (COVID-19). The 
first report of the novel coronavirus, SARS-CoV-2, 
originated in Wuhan, China, in early December 20191. 
Currently, there is no U.S. food and drug 
administration (FDA) approved drugs for the 
treatment of patients with COVID-19. A great deal of 
effort is ongoing to find effective therapeutics and 
preventive measures against this transmissible virus 
with high mortality. As result, available data are 
limited, and there are minimal randomized controlled 
trial (RCT) data on the efficacy of antiviral or 
immunomodulatory agents for the treatment of 
COVID-192. Most of the treatment protocols are based 
on observational studies and anecdotic reports3,4. 
Until now, there is no specific drug therapy available 
for the treatment of COVID-19. However, some 
potential anti-parasitic drugs like hydroxychloroquine 
and azithromycin, antifilarial drug Ivermectin and 
antiviral drugs have been tested by many research 
groups worldwide for their possible effect against the 
COVID-195. Ivermectin was a revolutionary drug in 
the 1980s, the forerunner of a new group of 
antiparasitic agents with activity against both parasitic 
nematodes and arthropods. Ivermectin has valuable 
public health applications for controlling 
strongyloidiasis and scabies and filariasis, through its 
effect on transmission6,7. Recent reports suggested that 
the treatment of COVID-19 by the single dose of 
Ivermectin was found to reduce the viral load up to 
5000 fold in vitro culture within 48 h8. Mechanism of 
action of this drug against COVID-19 is still unknown, 
but the impotant features of this drug is that no toxicity 
was observed during in vitro culture.  
Chloroquine (CQ) and hydroxychloroquine (HCQ) 
have been used to treat malaria for 70 years. 
Chloroquine (CQ) has showed low toxicity with strong 
inhibition on MERS-CoV and SARS-CoV9. 
Chloroquine likely accumulates in lysosomes, where it 
sequesters protons and increases the pH. The drug 
modulates immune response by interacting variety of 
host proteins and cellular processes.  
The HCQ is derivative of CQ, and is the first category 
drug which is prescribes for COVID-19 infection 
therapy10. This drug is a first line drug for malaria 
treatment and also has been used for rheumatoid 
arthritis and systemic lupus erythematosus treatment11. 
HCQ specific feature is affecting acid balance and can 
inhibit many enzymes. Moreover, it can obstruct the 
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viral post-translational modifications and glycosyl-
transferases12.  
Many Research centers and institutes all around the 
world have announced institutional guidelines for off-
label use of drugs for COVID-19, including CQ and 
HCQ with different dosages and duration for either 
treatment or prophylaxis, but there is no standard 
recommendation for prescribing these medications for 
this disease. In addition, CQ and HCQ have many side 
effects, including cardiac toxicity (QT prolongation, 
torsade de pointes, and ventricular arrhythmia), which 
may be harmful in the elderly, who are also high risk 
for COVID-1913.  
However, it is still not clear that whether these drugs 
have a better therapeutic effect, when compared to 
other drugs or combination therapy of multiple drugs. 
Consequently, this editorial makes comprehensive 
view on anti-parasitic drugs, which can be used in the 
current treatment COVID-19 disease. 
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